No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient ...

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood ...

SHELTON, CT, December 9, 2025 (EZ Newswire) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) today reported that ...

Gold is preparing for what may be its most powerful rally of the century. Four of the world’s biggest banks — Bank of America ...

Dhurandhar follows an Indian military operative who goes deep undercover in Pakistan in the mid-2000s, adopting the name ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General ...

Utilizing a >400 RFU threshold, treatment with leronlimab was associated with the upregulation of PD-L1 in CTCs and cancer-associated macrophage-like cells (CAMLs) in 76% (n=16/21) of patients overall ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

Results from CADENCE, the first and largest multinational prospective registry for patients with CAD/CAS, describe safety events observed in patients ...

Celldex (CLDX) announced the initiation of its global Phase 3 trial designed to establish the efficacy and safety of barzolvolimab in adult ...

(GLOBE NEWSWIRE) -- (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with ...